Risks versus benefits of medication use during pregnancy:What do women perceive? by Mulder, Bianca et al.
  
 University of Groningen
Risks versus benefits of medication use during pregnancy
Mulder, Bianca; Bijlsma, Maarten J; Schuiling-Veninga, Catharina Cm; Morssink, Leonard P;
van Puijenbroek, Eugene; Aarnoudse, Jan G; Hak, Eelko; de Vries, Tjalling W
Published in:
Patient Preference and Adherence
DOI:
10.2147/PPA.S146091
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2018
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Mulder, B., Bijlsma, M. J., Schuiling-Veninga, C. C., Morssink, L. P., van Puijenbroek, E., Aarnoudse, J. G.,
... de Vries, T. W. (2018). Risks versus benefits of medication use during pregnancy: What do women
perceive? Patient Preference and Adherence, 12, 1-8. https://doi.org/10.2147/PPA.S146091
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
© 2018 Mulder et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php 
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you 
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission 
for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Patient Preference and Adherence 2018:12 1–8
Patient Preference and Adherence Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
1
O r i g i n A l  r e s e A r c h
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/PPA.S146091
Risks versus benefits of medication use during 
pregnancy: what do women perceive?
Bianca Mulder,1 Maarten 
J Bijlsma,1 catharina cM 
Schuiling-Veninga,1 leonard 
P Morssink,2 Eugene van 
Puijenbroek,3,4 Jan g 
Aarnoudse,5 eelko hak,1 
Tjalling W de Vries6
1Groningen Research Institute of 
Pharmacy, Unit PharmacoTherapy, 
Epidemiology & Economics, 
University of Groningen, Groningen, 
the netherlands; 2Department 
of Obstetrics and Gynaecology, 
Medical center leeuwarden, 
leeuwarden, the netherlands; 
3Netherlands Pharmacovigilance 
centre lareb, ′s-Hertogenbosch, 
the netherlands; 4Unit of 
Pharmacotherapy and Pharmaceutical 
Care, Department of Pharmacy, 
University of Groningen, Groningen, 
the netherlands; 5Department 
of Obstetrics and Gynaecology, 
University Medical Center 
Groningen, University of Groningen, 
Groningen, the Netherlands; 
6Department of Pediatrics, Medical 
center leeuwarden, leeuwarden, 
the netherlands
Background: Understanding perception of risks and benefits is essential for informed patient 
choices regarding medical care. The primary aim of this study was to evaluate the perception 
of risks and benefits of 9 drug classes during pregnancy and associations with women’s 
characteristics.
Methods: Questionnaires were distributed to pregnant women who attended a Dutch Obstetric 
Care facility (first- and second-line care). Mean perceived risk and benefit scores were com-
puted for 9 different drug classes (paracetamol, antacids, antibiotics, antifungal medication, 
drugs against nausea and vomiting, histamine-2 receptor antagonists/proton pump inhibitors, 
antidepressants, nonsteroidal anti-inflammatory drugs, and sedatives/anxiolytics). For each 
participant, we computed weighted risk and benefit sum scores with principal component 
analysis. In addition, major concerns regarding medication use were evaluated.
Results: The questionnaire was completed by 136 women (response rate 77%). Pregnant women 
were most concerned about having a child with a birth defect (35%), a miscarriage (35%), or their 
child developing an allergic disease (23%), respectively, as a result of drug use. The majority 
of studied drug classes were perceived relatively low in risk and high in benefit. Higher risk 
scores were reported if women were in their first trimesters of pregnancy (p=0.007). Lower 
benefit scores were reported if women were single (p=0.014), smoking (p=0.028), nulliparous 
(p=0.006), or did not have a family history of birth defects (p=0.005).
Conclusion: Pregnant women’s concerns regarding potential drug adverse effects were not 
only focused on congenital birth defects but also included a wider range of adverse outcomes. 
This study showed that most of the studied drug classes were perceived relatively low in risk 
and high in benefit.
Keywords: drugs, perception, risks, benefits, worries, pregnancy
Background
The majority of pregnant women use medication during pregnancy.1 Despite increasing 
availability of information about teratogenic risks, medication use during pregnancy 
still causes uncertainty and concern among pregnant women and their health care 
providers.2,3
Recent risk perception studies observed that women tend to overestimate the 
magnitude of teratogenic risks.2–15 Although it is difficult to estimate the real risk 
of medication use during pregnancy, unrealistic perception of risk among pregnant 
women may lead to poor adherence, discontinuation of treatment, and even abortion 
of otherwise wanted and healthy infants.9,14 Counseling enables a more balanced deci-
sion on the use of medication during pregnancy.8,11,13 However, the manner in which 
information is presented can make a substantial difference to people’s responses. For 
example, providing pregnant women with positively framed information will lower risk 
correspondence: Bianca Mulder
Department of PharmacoEpidemiology 
and PharmacoEconomics, University 
Centre of Pharmacy, University of 
Groningen, PO Box XB45, A Deusinglaan 
1, 9713 AV Groningen, the Netherlands
Tel +31 50 361 7576
email biancamulder@outlook.com 
Journal name: Patient Preference and Adherence
Article Designation: Original Research
Year: 2018
Volume: 12
Running head verso: Mulder et al

































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1





perceptions significantly.8 In addition, women’s perception 
of the benefits of medication use may have a major influence 
on the acceptance of risks.
In previous risk perception studies, risk was often pre-
sented as the probability of having a child with a congenital 
malformation.4,12 Although congenital malformations are 
severe adverse effects, medication use during pregnancy has 
been associated with a broader spectrum of disorders than 
congenital malformations alone.16–18 The study of Petersen et 
al15 presented the risk of medication use as a harmful effect 
for the fetus. It is likely that many women may have inter-
preted harmful effects broadly and considered factors such 
as congenital anomalies, still birth, preterm birth, low birth 
weight, growth retardation of the fetus, and developmental 
delays in totality. However, it remains unknown what the 
major concerns are among pregnant women regarding 
medication use.
The primary aim of this study is to evaluate the percep-
tion of risks and benefits of medication use during pregnancy 
and associations with women’s sociodemographic character-
istics. In addition, we evaluated the major concerns among 
pregnant women regarding medication use.
Methods
Study design, setting, and study 
population
This study was based on data from a survey of pregnant 
women who attended an obstetric care facility (Medical 
Center Leeuwarden) in the Netherlands (both first- and 
second-line care). Yearly about 1,900 pregnant women (1.1% 
of all Dutch women) are cared for in this large (800 beds) 
teaching hospital in the northern part of the Netherlands. 
Researchers asked all pregnant women who were visiting the 
obstetric care facility for a consultation between May 1, 2013 
and June 30, 2013 to participate in the study. Questionnaires 
were distributed by the researchers to all women willing to 
participate, regardless of their health status or antenatal care 
needs. Inclusion criteria for participation in the study were 
that women had to be pregnant and had to understand the 
Dutch language. Women who could not understand Dutch 
were excluded.
Self-reported questionnaire
In this study, an anonymous self-reported questionnaire was 
developed and used. The questionnaire consisted of 4 parts 
to collect data on 1) general characteristics, 2) medication 
use during pregnancy and information sources used, 3) major 
concerns related to medication use, and 4) perceived risks 
and benefits of medication use during pregnancy. In Dutch 
health care, first-line care is easily accessible and patients 
can contact first-line care providers without a referral. 
Second-line care is specialist care in hospitals where pregnant 
women need a referral from a general practitioner (GP) or 
a midwife.
A group of 10 pregnant women were asked to pretest a 
tested version of the questionnaire. They were interviewed 
to confirm if the questionnaire was clear to them and if they 
had comments or suggestions to state in the text box given 
at the end of the questionnaire. No specific comments were 
returned, so we concluded that the test version was good and 
no further changes were required. Since waiting times were 
often extensive, questionnaires could easily be completed 
by the participants.
Part 1 – general characteristics
Sociodemographic variables included in the questionnaire 
were age, education, marital status, duration of the preg-
nancy, gravidity, parity, status of employment, and attending 
first or second-line care facility. Lifestyle variables that 
were examined were the use of alcohol and smoking during 
pregnancy.
Part 2 – medication use during pregnancy 
and information sources used
Respondents were asked whether and which medication 
they used with and without a prescription during pregnancy. 
Classes of drugs were presented, including examples of 
generic and trade names. Presented drug classes were 
paracetamol, nonsteroidal anti-inflammatory drugs (NSAIDs), 
vitamins other than folic acid and vitamin D, drugs against 
a cold, acid-suppressive medication, antibiotics, antifungal 
medication, drugs against nausea and vomiting (NVP), 
sedatives/anxiolytics, anti-asthma medication, anti-diabetes 
medication, medication against high blood pressure, and 
homeopathic medication.19
Folic acid and vitamin D are vitamins which are advised 
in the Netherlands during pregnancy.20 Therefore, women 
who only used these vitamins were categorized as non-
medication users. When prenatal vitamins were reported, 
we considered them as multivitamins designed for pregnant 
women containing more and/or other vitamins than folic 
acid and vitamin D.
Women were asked if they obtained information about 
medication before and during pregnancy. Commonly used 
sources of information were listed: Internet, gynecologist, 
GP, pharmacist, midwife, package information leaflets (PIL), 
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Perception of risks and benefits of medication during pregnancy
Part 3 – measurements of concerns
Women were asked to rate their level of concern about having 
a miscarriage, preterm birth, complicated delivery, child with 
a birth defect, or a child with a low gestational age as a result 
of medication use during pregnancy. In addition, women 
were asked to rate their level of concern about having a child 
with memory/learning problems, behavioral problems, or an 
allergic disease. These events are not evident at birth, but 
are associated with medication use during pregnancy in the 
literature.16–18,21 Women could rate their level of concern with 
a score from 1 to 5 on a 5-point scale (Table 1).21
Part 4 – perceived risks and benefits 
of medication use during pregnancy
Different studies on risk perception proposed that risk is 
dependent on the expectancy of the probability of an event 
and the beliefs about the potential harm.12,22–27 In this study, 
women were asked to rate the probability and severity of 
an event occurring due to exposure to several drug classes 
(paracetamol, antacids, antibiotics, antifungal medica-
tion, drugs against NVP, histamine-2 receptor antagonists/
proton pump inhibitors, antidepressants, NSAIDs, sedatives/
anxiolytics) on a 7-point Likert scale (Table 1).27 For each 
drug class, examples of generic (domperidone, metoclo-
pramide, ibuprofen, diclofenac, naproxen, nitrofurantoin, 
amoxicillin, cimetidine, pantoprazole, omeprazole, citalo-
pram, paroxetine, amitriptyline, temazepam, oxazepam, 
diazepam, miconazole and clotrimazole) or trade names 
(Motilium, Primperan, Rennie, Gaviscon, Furabid, Cipramil, 
Seroxat, Canesten) were given. Risk scores were obtained by 
multiplication of the measures of perceived probability and 
severity. A square root extraction was performed to make the 
risk scores comparable with the benefit scores.23
To get information on the perceived benefits of medica-
tion during pregnancy, women were asked to rate the benefits 
of the drug classes on a scale from 1 to 7 (Table 1).
Statistical analysis
Percentages were computed for the respondents who were 
concerned or very concerned (scored 4 or 5 on the concern 
scale) about having a miscarriage, preterm birth, complicated 
delivery, child with a birth defect, or a child with a low ges-
tational age as a result of medication use during pregnancy. 
Means and standard deviations (SDs) were computed for the 
perceived risk (probability times severity score) and benefit 
scores of the different drug classes. We also calculated 
Pearson’s correlation coefficients between risk and benefit 
scores for each separate drug class.
Separate principal component analyses (PCA) were per-
formed on the 9 different drugs on the risk scale and benefit 
scale, respectively. PCA was used to construct weighted 
risk and benefit sum scores using the loadings of the first 
principal component as weights.28,29 With this construction, 
the weighted sum scores represent unbiased estimates of stan-
dardized values on a latent variable (eg, “overall perceived 
benefit”). The loadings are used as weights because the size 
of each loading indicates the degree to which a variable rep-
resents an aspect of the underlying latent variable. Given the 
relatively high proportion of variance explained by each first 
principal component, we take their respective latent variables 
to represent “overall” risk and benefit, respectively. The first 
principal component on the risk scale explained 58.5% of 
the variance, whereas the first principal component of the 
benefit scale explained 53.4% of the variance. Barlett’s test 
of sphericity and the Kaiser–Meyer–Olkin (KMO) test were 
performed to test if the number of significant correlations was 
sufficient to perform PCA.28 Bartlett’s test of sphericity was 
significant (p,0.001) for the 3 scales. KMO statistic showed 
that a factor analysis was appropriate for the risk and benefit 
scales (0.833 and 0.859, respectively).29
Linear regression models were used to examine associa-
tions between maternal age, education level, and the weighted 
risk and benefit sum score. Student’s t-test was performed to 
assess differences in the weighted risk and benefit sum score 
for the different general characteristics, medication use, and 
acquirement of information. All analyses were performed 
using the SPSS software for Windows (version 21; IBM 
Corporation, Armonk, NY, USA).
Table 1 Questions and scales on which concerns related to 
medication use, probability, severity, and benefits were rated
Items Questions Scale
concerns To what extent are you 
concerned that there is an 
increased probability that this 
event occurs as a result of 
medication use? 
1= never concerned, 
2= sometimes 
concerned, 3= neutral, 
4= often concerned, and 
5= always concerned
Probability How likely do you think an 
accident or unfortunate event 
involving this drug occurs?
1= very unlikely; 
7= very likely
Severity if an accident or unfortunate 
event involving this drug 
occurred, to what extent are 
the harmful effects for the 
baby and/or mother?
1= very mild harm; 
7= very serious harm
Benefits How beneficial do you 
consider this drug or item to 
be for pregnant women and 
their babies?
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The institutional review board of the Medical Center 
Leeuwarden stated that ethical approval and patient informed 
consent were not required, since the study involved a ques-
tionnaire only, was completely anonymous, and no patient 
data were used. However, the study was approved by the insti-
tutional review board of the Medical Center Leeuwarden.
Results
Response and general characteristics
During the 2 months when the questionnaire was distributed, 
177 women were informed about the study. The questionnaire 
was returned by 136 women (77%). Data on general char-
acteristics of the study population are provided in Table 2. 
The mean age of the respondents was 30.8 (SD ±5) years. 
Most of the respondents (55%) participated in the study while 
they were in their third trimester of pregnancy. Most of the 
respondents had been pregnant before (72%) and 30% of the 
respondents had had a previous miscarriage.
Medication use
Most of the women (82.2%) had used medication during 
pregnancy (Table 3). Paracetamol was used most commonly 
during pregnancy (42%). Other commonly used drugs were 
vitamins (21%), acid-suppressive medication (25%), and antibiotics (10%). Of the respondents, 56 (48%) reported folic 
acid and/or vitamin D use during pregnancy. Information 
about medication was obtained by 76 women (67%). Most 
used information sources were the Internet, PIL, and GP.
concerns
Pregnant women were most concerned (score 4 or 5 on 
the concern score) about having a child with a congenital 
birth defect (35%), having a miscarriage (35%), or having 
a child with an increased risk of an allergic disease (23%), 
respectively, as a result of their drug use. The different con-
cerns pregnant women had regarding medication use during 
pregnancy are presented in Figure 1.
Perceptions of risk and benefits
Highest risk scores were reported for antidepressants, seda-
tives/anxiolytics, and NSAIDs, respectively. Highest benefit 
scores were reported for antibiotics, antifungal medication, 
and antacids. Mean risk and benefit scores, including Pear-
son correlation coefficients, are presented in Figure 2. Risks 
and benefit scores were significantly inversely correlated 
for most of the drug classes. Almost half of the drug classes 
were perceived as low in risk (mean score ,3.5) and high 
in benefit (mean score .3.5). In addition, Figure 2 shows 
Table 2 General characteristics of study population (N=136)
Characteristics Number (%)
Mean age ± SD (years) 30.8±5.0
Marital status: married/cohabiting 126 (92.6)
Duration of pregnancy*
First trimester 16 (13.8)
second trimester 36 (31.0)
Third trimester 64 (55.2)
Nulliparity 39 (28.7)
Previous miscarriages 41 (30.1)
Presence of birth defects in first-degree family 26 (19.1)
education
low level of education 21 (15.4)
Medium level of education 53 (39.0)
High level of education 62 (45.6)
Working status
Not working in health care sector 78 (57.4)
Working in health care sector 31 (22.8)
Not working 27 (19.9)
Attended
First-line care facility 24 (17.6)
Second-line care facility 111 (81.6)
Smoking during pregnancy 15 (11.0)
Alcohol consumption during pregnancy 0 (0.0)
Note: *Information on trimester of pregnancy is missing for 2 respondents.
Table 3 Reported medication use during pregnancy (N=136)






Total 97 (82.2) 66 (48.5) 69 (58.5)
Paracetamol 49 (41.5) 11 (8.1) 41 (34.7)
Vitamins other than folic 
acid and vitamin D
25 (21.2) 0 25 (21.2)
Acid-suppressive medication 30 (25.4) 10 (7.4) 21 (17.8)
Antacids 24 (20.3) 4 (2.9) 21 (17.8)
H2-antagonists/PPIs 6 (4.4) 6 (4.4) 0
Antibiotics 11 (8.1) 11 (8.1) 0
nsAiDs 1 (0.7) 1 (0.7) 0 (0.0)
Antifungal medication 7 (5.1) 7 (5.1) 1 (0.8)
Antidepressants 5 (4.2) 5 (4.2) 0
cardiovascular medication 8 (5.9) 8 (5.9) 0
Anti-diabetes medication 4 (2.9) 4 (2.9) 0
Anti-allergy medication** 6 (4.4) 6 (4.4) 0
laxatives 6 (4.4) 6 (4.4) 0
iron supplementation 10 (8.5) 10 (8.5) 0
Thyrax 9 (7.6) 9 (7.6) 0
Anti-cold medication 10 (8.5) 0 10 (8.5)
Other 22 (16.2) 15 (11.0) 10 (7.4)
Notes: *Women could have used both on prescription and OTC medication; 
hence, the number for total medication use is lower than the sum of on prescription 
and OTC medication use. **This group contains medication for the treatment of 
eczema, asthma, or hay fever.
Abbreviations: OTc, over the counter; PPis, proton pump inhibitors; nsAiDs, 
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Perception of risks and benefits of medication during pregnancy
that the spread of mean values of the different drugs on the 
risk scale is higher (from 1.9 to 5.3) than the spread of mean 
values of the different drugs on the benefit scale (from 3.3 
to 4.7).
Analysis of the weighted sum risk score showed that 
women in the first 2 trimesters of pregnancy perceived 
significantly higher risks of medication use (p=0.007). The 
remaining characteristics, namely, education, maternal age, 
employed in health care sector, nulliparity, previous miscar-
riages, smoking during pregnancy, and use of medication 
showed no statistically significant differences in weighted 
risk sum scores. Lower benefit scores of medication use were 
perceived if women were single (p=0.014), smoking during 
pregnancy (p=0.028), nulliparous (p=0.006), or did not have 
a family history of birth defects (p=0.005).
Discussion
Main findings
Women were most concerned that medication use during 
pregnancy could result in a child with a congenital birth 
defect, a miscarriage, or a child with an allergic disease. Most 
of the drug classes were perceived relatively low in risk and 
high in benefit. Only antidepressants, sedatives/anxiolytics, 
and NSAIDs were perceived as high-risk medication. Women 
had higher risk perception scores during early trimesters of 
pregnancy. Lower benefit scores were perceived if women 
were single, nulliparous, smoking during pregnancy, or had 
no family history of birth defects.
Strengths and limitations
Our study is the first to investigate the perceived risk–benefit 
balance with regard to medication use during pregnancy. 
Another major strength of our study is the method of inclu-
sion. In previous risk perception studies, women were invited 
to participate in the studies when visiting websites contain-
ing pregnancy-related information.12,15 In our opinion, this 
could have led to a selection bias and the inclusion of more 
concerned women. Since women were included independent 
of their information seeking behavior in the current study, 
the influence of this type of selection bias will likely be less. 
The women included in the study were representative of the 
general Dutch population of pregnant women with respect 
to age (age of the general pregnant population was 31 years 
vs 31 years in this study population) and education level 
(high education of 40% in the general population vs 42% 
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Figure 2 Means of the perceived risk and perceived benefits of different medication 
groups during pregnancy.
Abbreviations: NVP, nausea and vomiting during pregnancy; H2A/PPI, histamine-2 
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asked to fill out the questionnaire while they were pregnant. 
With this approach, the outcome of the pregnancy could not 
have influenced their risk perceptions. It should, however, be 
noted that most women completed the questionnaire while 
they were in their third trimester. In the third trimester, the 
likelihood of an abortion is low and congenital anomalies 
already may have been detected via ultrasound. In addition, 
recall bias regarding medication use will be minimal when 
asked during pregnancy.32 Another strength of our study is 
the questionnaire design, because information about medica-
tion use was obtained with both open and closed questions. 
It has been reported that prevalence estimates are higher 
when questions include indications or specific drugs when 
compared to open-ended questions.33 The use of the weighted 
risk and benefit sum scores was another advantage of this 
study. The weighted sum scores represent unbiased estimates 
of standardized values on a latent variable (eg, “overall 
perceived benefit”).
Apart from these strengths, potential limitations need to 
be discussed. First, we included all pregnant women who 
were attending first and second-line care facilities, regardless 
of their health status or antenatal care, to reduce the risk of 
sampling bias. Although every pregnant woman living in the 
Netherlands can undergo a prenatal screening, the majority 
of our study population consisted of women who came for a 
routine follow-up with an obstetrician. We could, therefore, 
not exclude the possibility that the study population differed 
from the general birthing population. Nevertheless, as stated 
above, the distribution of age and level of education was 
similar between the study population and the general birthing 
population in the Netherlands.30,31
Second, all women understood the Dutch language; 
however, the extent to which they understood the questions 
that were asked was not assessed.
Third, though the response rate was rather high for a 
questionnaire study (77%) and associations were significant 
in most evaluations, the total number of participants was 
low. Due to the low statistical power, we could not perform 
comparisons between women who were prescribed specific 
drugs and women who were not. Such analyses would show 
how actual users balance the risks and benefits of a specific 
drug and would represent the potential noncompliance in 
that population.
Fourth, we compared risks and benefits for drug classes 
instead of specific drugs within the drug classes. In rela-
tion to the measurement of concerns, questions were asked 
about concerns for “any medication” rather than concerns 
related to a specific medication. This made our questions 
more comprehensible by pregnant women; however, since 
there may be variation within and between each drug class, 
findings cannot be interpreted for specific drugs. We did 
not provide the option of “do not know” when asked for 
the perception of risks and benefits. The number of unfilled 
responses regarding risks and benefits was low and ranged 
from 4 (paracetamol) to 9 (drugs against NVP) for questions 
about risks and ranged from 3 (paracetamol) to 6 (antibiotics) 
for the questions about benefits. It is also possible that 
participants listed the mid-value if they did not know the 
medication group described. It is unclear to what extent this 
influenced the results.
Fifth, interpretations were given only for scores 1 and 7 
of the 7-point Likert scales. It is not correct to infer that the 
intensity of feeling between 1 and 7 is equivalent to the inten-
sity of feeling between other consecutive categories on the 
Likert scale. It could not be excluded that the differences in 
the perception of risks and benefits were due to interpersonal 
differences in interpretation of the values of the scale.
Sixth, the reliability and validity of the questionnaire were 
not assessed and it is unclear how this could have affected 
the results of this study.
interpretation and comparison 
with literature
Women were most concerned that medication use during 
pregnancy could result in a child with a birth defect, a miscar-
riage, or a child who develops an allergic disease. Although 
different studies have investigated the different worries 
of pregnant women in general,21 this is the first study that 
reports women’s concerns regarding medication use during 
pregnancy.
Different studies reported that risks associated with 
medication use were perceived higher than actual risks.2–15 
However, it has been considered that the relativeness of risk 
perceptions is more interesting than the mean risk perceptions 
itself.12 From the different drug classes, sedatives and anti-
depressants were perceived highest in risk and paracetamol 
and antacids were perceived lowest. This is in accordance 
with findings from a recent study in Norway.12 In the current 
study, women were not asked to rate the absolute risks of 
the different drug classes and the results of this study cannot 
be compared with true risks. However, for the drug classes 
perceived highest in risk, teratogenicity has been described in 
the literature and the product information of several products 
from these classes.
Recent studies have shown that pregnant women overes-
timate the teratogenic risk of medication use.2–15 However, 
this study showed that women perceive benefits of medica-
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Perception of risks and benefits of medication during pregnancy
most of the drugs were perceived relatively low in risk 
and high in benefit. Risks and benefits were significantly 
negatively correlated for most of the drugs. This confound-
ing of risks and benefits in women’s minds may implicate 
that it is possible to change the risk perception by changing 
the perception of benefits of medication use.33 The variance 
of perceived risks was higher than the variance of perceived 
benefits between the different drug classes (Figure 2). That 
risk scores were rated with more extreme values than the 
benefit scores may indicate that women have more difficulty 
rating the benefits of medication use than the risks. Includ-
ing more information about the benefits of medication use 
during counseling may play an important role in lowering 
risk perceptions among pregnant women.34
Analyses of the weighted risk sum score showed that 
women perceived higher risks during the first 2 trimesters of 
pregnancy than women in the third trimester of pregnancy. 
In the first trimester, organogenesis takes place and risks on 
spontaneous abortion and congenital anomalies are highest. 
However, recently it has been stated that exposures during 
the third trimester can also have negative implications for 
the child for certain pediatric outcomes.16,17
Analyses of the weighted benefit sum score showed that 
women perceived lower benefit scores if they were single, 
smoking, or nulliparous. Since no earlier research focused 
on the potential benefits of medication use during pregnancy, 
we can only speculate about potential explanations. Single 
women lack the option to discuss their concerns and fears with 
a partner, which may contribute to a more cautious attitude 
toward medication use during pregnancy and lower perceived 
benefit scores. Nulliparous women may also have a more 
cautious attitude toward medication use during pregnancy, 
since they had never experienced a pregnancy before. In 
addition, a previous study performed in Norway found that 
nulliparous women perceived higher risks of medication use 
during pregnancy.12 Women who smoked during pregnancy 
more often tend to have a low socioeconomic status. In 
addition, the vision of these women on a healthy pregnancy 
may be different, since they maintain an unhealthy lifestyle 
even when they are pregnant. They may therefore not fully 
comprehend the potential benefits of medication use during 
pregnancy. Moreover, none of the women indicated having 
consumed alcohol during pregnancy, which is unlikely. The 
influence of response bias cannot be ruled out and it is unclear 
how this could affect the results.
Women with a family history of birth defects perceived 
higher benefit scores of medication use during pregnancy. 
These women may have more knowledge about medication use 
during pregnancy, especially about the benefits. For example, 
they may be aware that folic acid supplementation may 
prevent certain birth defects.
Conclusion
This study shows that concerns regarding medication use 
during pregnancy are not restricted to having a child with 
a congenital birth defect only. Although pregnant women 
overestimate the teratogenic risk of medication use, most 
of the drugs were perceived relatively low in risk and high 
in benefit. Health care providers can take this into account 
when counseling pregnant women.
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